Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting

NEXT STORY
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
PREV STORY
SetPoint Medical to Present Results From The U.S. Pilot Study in Rheumatoid Arthritis Patients at European Congress of Rheumatology (EULAR) 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Signature Resources Provides a Project Update on Ongoing Drilling Activities at Its 100% Owned Lingman Lake Gold Project

author_avatar
NASDAQ Market News

Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018

FREMONT, Calif., July 26, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a ...

author_avatar
NASDAQ Market News

Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury

author_avatar
NASDAQ Market News